Michael joined the BUBBL group in September 2015 primarily to work on a Phase-1 clinical trial of ultrasound-mediated targeted drug delivery for treatment of liver cancer. His current research efforts include a Phase-1 trial of ultrasound-triggered drug delivery to pancreatic tumours, clinical translation of quantitative cavitation monitoring techniques, and development of devices to enable the use of sound, magnetism, and light for targeted drug delivery.
Michael earned his doctorate from the Georgia Institute of Technology in 2015 after designing and demonstrating an ultrasonic system for deep tissue elastography. Over the preceding 23 years, Michael was a research engineer and principal investigator at Georgia Tech, working in research areas including submarine sonar, cetacean soft tissue characterization, photoacoustics, fish hearing, and non-destructive structural evaluation.
